SUPN Long Call Strategy
SUPN (Supernus, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
SUPN (Supernus, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.73B, a trailing P/E of 7.79, a beta of 0.52 versus the broader market, a 52-week range of 25.92-43.2, average daily share volume of 2.5M, a public-listing history dating back to 2012, approximately 827 full-time employees. These structural characteristics shape how SUPN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.52 indicates SUPN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 7.79 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price. SUPN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on SUPN?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
SUPN snapshot
As of November 13, 2026, spot at $29.69, ATM IV 64.60%, IV rank 31.97%, expected move 18.52%. The long call on SUPN below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on SUPN specifically: SUPN IV at 64.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 18.52% (roughly $5.50 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SUPN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SUPN should anchor to the underlying notional of $29.69 per share and to the trader's directional view on SUPN stock.
SUPN long call setup
The SUPN long call below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SUPN at $29.69 on that close, the first option leg uses a $29.87 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SUPN chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SUPN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $29.87 | $2.48 |
SUPN long call risk and reward
- Net Premium / Debit
- -$247.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$247.50
- Breakeven(s)
- $32.35
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
SUPN long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on SUPN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$247.50 |
| $6.57 | -77.9% | -$247.50 |
| $13.14 | -55.8% | -$247.50 |
| $19.70 | -33.6% | -$247.50 |
| $26.26 | -11.5% | -$247.50 |
| $32.83 | +10.6% | +$48.26 |
| $39.39 | +32.7% | +$704.61 |
| $45.95 | +54.8% | +$1,360.96 |
| $52.52 | +76.9% | +$2,017.31 |
| $59.08 | +99.0% | +$2,673.67 |
When traders use long call on SUPN
Long calls on SUPN express a bullish thesis with defined risk; traders use them ahead of SUPN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
SUPN thesis for this long call
The market-implied 1-standard-deviation range for SUPN extends from approximately $24.19 on the downside to $35.19 on the upside. A SUPN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current SUPN IV rank near 31.97% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on SUPN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SUPN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SUPN-specific events.
SUPN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SUPN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SUPN alongside the broader basket even when SUPN-specific fundamentals are unchanged. Long-premium structures like a long call on SUPN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current SUPN chain quotes before placing a trade.
Frequently asked questions
- What is a long call on SUPN?
- A long call on SUPN is the long call strategy applied to SUPN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With SUPN stock at $29.69 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed SUPN chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are SUPN long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the SUPN long call priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 64.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$247.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SUPN long call?
- The breakeven for the SUPN long call priced on this page is roughly $32.35 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The SUPN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 18.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on SUPN?
- Long calls on SUPN express a bullish thesis with defined risk; traders use them ahead of SUPN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current SUPN implied volatility affect this long call?
- SUPN ATM IV is at 64.60% with IV rank near 31.97%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.